Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bakris

Showing results (591-600 of 738) with videos related to

Pageof 74
Sort By:
JACC. Advances|March 30, 2026
Worsening Kidney Function and Cardiovascular Outcomes in Type 2 Diabetes and Atherosclerotic DiseaseAbhinav Sharma, Amir Razaghizad, Susanna R Stevens, et al.
Journal of the American College of Cardiology|January 18, 2023
Albuminuria and Heart Failure: JACC State-of-the-Art ReviewMuhammad Shahzeb Khan, Izza Shahid, Stefan D Anker, et al.
Clinical Diabetes : a Publication of the American Diabetes Association|May 2, 2024
Diabetic Kidney Disease Prevention Care Model DevelopmentNuha A ElSayed, Raveendhara R Bannuru, George Bakris, et al.
Diabetes, Obesity & Metabolism|October 10, 2023
Efficacy of finerenone in patients with type 2 diabetes, chronic kidney disease and altered markers of liver steatosis and fibrosis: A FIDELITY subgroup analysisNikolaos Perakakis, Stefan R Bornstein, Andreas L Birkenfeld, et al.
Blood Pressure|August 12, 2011
Predictors of systolic BP <140 mmHg and systolic BP level by randomly assigned treatment group (benazepril plus amlodipine or hydrochlorothiazide) in the ACCOMPLISH StudySverre E Kjeldsen, Kenneth A Jamerson, George L Bakris, et al.
JAMA|November 13, 2004
Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trialGeorge L Bakris, Vivian Fonseca, Richard E Katholi, et al.
Archives of Internal Medicine|June 15, 2007
Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP)Peter A McCullough, Claudine T Jurkovitz, Pablo E Pergola, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|November 6, 2007
Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI TrialJackson T Wright, George L Bakris, David S H Bell, et al.
Journal of the Cardiometabolic Syndrome|December 2, 2008
Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in patients with type 2 diabetes and hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) studyRobert A Phillips, Vivian Fonseca, Richard E Katholi, et al.
American Journal of Nephrology|February 7, 2018
Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes StudyMelanie P Chin, George L Bakris, Geoffrey A Block, et al.
Pageof 74

Showing results (591-600 of 738) with videos related to

Sort By:
Pageof 74
JACC. Advances|March 30, 2026
Worsening Kidney Function and Cardiovascular Outcomes in Type 2 Diabetes and Atherosclerotic DiseaseAbhinav Sharma, Amir Razaghizad, Susanna R Stevens, et al.
Journal of the American College of Cardiology|January 18, 2023
Albuminuria and Heart Failure: JACC State-of-the-Art ReviewMuhammad Shahzeb Khan, Izza Shahid, Stefan D Anker, et al.
Clinical Diabetes : a Publication of the American Diabetes Association|May 2, 2024
Diabetic Kidney Disease Prevention Care Model DevelopmentNuha A ElSayed, Raveendhara R Bannuru, George Bakris, et al.
Diabetes, Obesity & Metabolism|October 10, 2023
Efficacy of finerenone in patients with type 2 diabetes, chronic kidney disease and altered markers of liver steatosis and fibrosis: A FIDELITY subgroup analysisNikolaos Perakakis, Stefan R Bornstein, Andreas L Birkenfeld, et al.
Blood Pressure|August 12, 2011
Predictors of systolic BP <140 mmHg and systolic BP level by randomly assigned treatment group (benazepril plus amlodipine or hydrochlorothiazide) in the ACCOMPLISH StudySverre E Kjeldsen, Kenneth A Jamerson, George L Bakris, et al.
JAMA|November 13, 2004
Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trialGeorge L Bakris, Vivian Fonseca, Richard E Katholi, et al.
Archives of Internal Medicine|June 15, 2007
Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP)Peter A McCullough, Claudine T Jurkovitz, Pablo E Pergola, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|November 6, 2007
Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI TrialJackson T Wright, George L Bakris, David S H Bell, et al.
Journal of the Cardiometabolic Syndrome|December 2, 2008
Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in patients with type 2 diabetes and hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) studyRobert A Phillips, Vivian Fonseca, Richard E Katholi, et al.
American Journal of Nephrology|February 7, 2018
Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes StudyMelanie P Chin, George L Bakris, Geoffrey A Block, et al.
Pageof 74